First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961.

Key facts

Study ID
NCT03309241
Run by
Pfizer
People needed
25
Starts
2017-10-17
Expected to finish
2018-03-22
Last updated by the study team
2018-04-02

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.